miR-181b的潜在复制的生物标志物，进展慢性HBV

StephenW

miR-181b potential biomarker of replication, progression in chronic HBV
Published on June 1, 2015 at 5:15 PM · No Comments


By Shreeya Nanda, Senior medwireNews Reporter

A Chinese team reports a correlation between serum levels of microRNA (miR)-181b and hepatitis B virus (HBV) replication and disease progression in patients with chronic HBV infection.

Researchers Peihong Dong and Jianjian Zheng, from The First Affiliated Hospital of Wenzhou Medical University in Zhejiang, and study co-authors say that their findings “support the development of serum miR-181b as a marker for disease progression” in this patient population.

They explain in Digestive Diseases and Sciences that miR-181b was the focus of the study “owing to its pro-fibrosis ability, as well as the earlier finding that serum levels may be a potential diagnostic biomarker for cirrhosis.”


Serum levels of miR-181b were significantly higher in the 64 chronic HBV patients than in the 72 healthy controls, at a median of 2.550 versus 0.920 (p<0.0001).

There was also a correlation with HBV DNA replication – patients positive for hepatitis B e antigen (HBeAg) had significantly elevated serum miR-181b levels compared with HBeAg-negative patients (2.905 vs 2.315; p<0.0001). As did participants with liver HBV DNA levels above compared with below the threshold of 2.282 IU/cell (3.570 vs 2.295; p<0.0001).

Moreover, multivariate analysis showed that serum miR-181b levels were significantly associated with a histological activity index over 8 (p=0.009) and a fibrosis score over 4 (p=0.001), “highlighting its potential as an independent predictor of moderate and severe [chronic hepatitis B] disease”, say the researchers.

“This may be explained by the fact that higher serum miR-181b levels are induced at higher levels of HBV DNA, which is often associated with more severe liver disease”, they add.

Highlighting the small sample size of their study, the team concludes: “Studies with larger sample sizes are warranted to validate the efficacy of this marker and determine the relationship between serum miR-181b and patient immune status.”

medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2015

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


Posted in: Medical Research News

Tags: Antigen, Biomarker, Cell, Cirrhosis, DNA, DNA Replication, Fibrosis, Healthcare, Hepatitis B, Hepatitis B Virus, Hospital, Liver Disease, microRNA, Stroke, Virus
Permalink | Comments (0)

StephenW

的miR-181b的潜在复制的生物标志物，进展慢性HBV
发表于2015年6月1日在5:15 PM·没有评论


通过Shreeya南大，高级medwireNews记者

中国队的报告与慢性HBV感染的小分子RNA（MIR）-181b和乙肝病毒（HBV）的复制和疾病进展的血清水平之间的相关性。

研究人员培红董健健和郑，来自温州医学院大学在浙江第一附属医院和研究的共同作者说，他们的发现“支持血清的miR-181b的发展作为一个标志为疾病进展”，在这个病人的人口。

他们在消化系统疾病和科学解释的miR-181b的是研究的重点“由于其亲纤维化的能力，以及早期发现，血清水平可能是一个潜在的诊断肝硬化的生物标志物。”


的miR-181b的血清水平显著高于64慢性乙型肝炎患者比在72名健康对照，以2.550 0.920相比（P <0.0001）的中位数。

也有人对HBV DNA复制的相关性 - 阳性患者乙肝e抗原（HBeAg）有显著升高血清中的miR-181b的水平与HBeAg阴性患者相比（2.905 VS 2.315，P <0.0001）。象参与者肝脏HBV DNA水平以上低于2.282国际单位/细胞的阈值进行比较（3.570 VS 2.295; P <0.0001）。

此外，多因素分析表明，血清的miR-181b的水平显著与组织学活动指数超过800（P = 0.009）和纤维化评分超过4（P = 0.001），“突出了其作为潜在的中度和重度的独立预测因子[慢性乙型肝炎]病“，研究人员说。

“这可以通过以下事实更高的血清的miR-181b的水平被诱导在较高水平的HBV DNA，其通常与更严重的肝脏疾病相关的解释”，他们补充。

突出了他们研究的样本量小，团队总结道：“是研究具有较大的样本量来保证验证此标记的疗效及测定血清的miR-181b的和患者免疫状态之间的关系。”

medwireNews是由Springer医疗保健有限公司提供了一个独立的医疗新闻服务。 ©斯普林格保健品有限公司; 2015年

从medwireNews与施普林格医疗保健用品有限公司©斯普林格保健有限公司保留所有权利许可授权。无论这些政党的认可或推荐任何商业产品，服务或设备。


发表在：医学研究新闻

标签：抗原，生物标志物，细胞，肝硬化，DNA，DNA复制，纤维化，医疗保健，乙肝，乙型肝炎病毒，医院，肝病，微小RNA，中风，病毒
固定链接|评论（0）

君看一叶舟

他们引用的中国温州医科大学的研究成果

君看一叶舟

一个中国研究团队报告了mir-181b血清水平和HBV感染者的病毒复制水平和病情进展有关。